Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gilead Sciences, Inc. (GILD) vs Vanguard Value Index Fund ETF (VTV) Price & Performance

Gilead Sciences, Inc.Trade
Vanguard Value Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Gilead Sciences, Inc. vs Vanguard Value Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $136.08 (market cap $168.35B), while Vanguard Value Index Fund ETF trades at $226.1. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

GILDVTV
Market Cap
$168.35B
Sector
Health
52-Week High
$155.80$225.35
52-Week Low
$110.56$179.43
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $136.73, up 2.76% on the day, with a bullish technical signal and strong analyst consensus. Recent Q2 2026 earnings beat revenue estimates despite a net loss driven by acquisition costs, while HIV drug sales and raised guidance provide fundamental support. The stock is near its pivot point of $136, with resistance at $137 and support at $134.

Outlook remains positive given robust HIV franchise growth and pipeline advancements, but risks include patent cliffs, high debt, and profitability volatility. With 67% of analysts rating it a Buy and a consensus price target of $151.22, the stock offers potential upside, though investors must weigh execution risks against growth catalysts.

Vanguard Value Index Fund ETF

VTV trades at $225.71, up 0.31% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced exposure. A dividend of $1.08 is scheduled for June 2026, adding income appeal.

The value rotation narrative supports VTV's momentum, though RSI levels indicate potential near-term overbought conditions. Risks include sector concentration and market volatility. Analyst sentiment remains positive given the ETF's diversification and current market trends favoring value strategies over tech-heavy indexes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD

About Vanguard Value Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VTV